Han Rui, Wei Wenguang
Department of Pharmacy, The First People's Hospital of Changzhou, Changzhou, China.
Department of Acupuncture, The First People's Hospital of Changzhou, No.185, Juqian Street, Changzhou, 213003, Jiangsu, China.
J Mol Neurosci. 2025 Aug 9;75(3):102. doi: 10.1007/s12031-025-02394-9.
Insomnia, a common complication following stroke, significantly impairs patients' clinical outcomes. Electroacupuncture (EA), an advanced acupuncture technique, has demonstrated efficacy in alleviating insomnia symptoms. Agomelatine (AT), a melatonin receptor agonist, is widely utilized for depression management. This study aimed to evaluate the therapeutic effects of combined EA + AT therapy for post-stroke insomnia. A total of 120 stroke-related insomnia patients were randomly assigned to three intervention groups (n = 40 each): EA therapy, AT treatment, and EA + AT combination therapy. Sleep efficiency and cognitive function were comprehensively assessed using the Cardiopulmonary Coupling-based sleep quality evaluation system, Montreal Cognitive Assessment (MoCA), and National Institutes of Health Stroke Scale (NIHSS). The results revealed that all three interventions significantly enhanced sleep efficiency (EA: 78.23 ± 4.19; AT: 75, 5; EA + AT: 80.97 ± 4.21) and MoCA scores (EA: 24, 2; AT: 24, 2; EA + AT: 27, 2), with the combination therapy showing superior effectiveness. Similarly, NIHSS scores exhibited marked reduction across all treatment groups (EA: 6, 2; AT: 7, 2), particularly in the EA + AT combination cohort (EA + AT: 4, 3). Notably, post-treatment analysis revealed significant positive correlations between sleep efficiency and MoCA scores in all groups, with the strongest correlation observed in the AT group (r = 0.87). These findings demonstrate that EA + AT combination therapy outperforms monotherapies in treating post-stroke insomnia. In conclusion, this study establishes EA + AT as an effective intervention for improving both sleep quality and cognitive function in stroke-related insomnia patients, offering a promising therapeutic strategy for this clinical condition.
失眠是中风后的常见并发症，严重影响患者的临床预后。电针（EA）作为一种先进的针刺技术，已被证明在缓解失眠症状方面具有疗效。阿戈美拉汀（AT）是一种褪黑素受体激动剂，广泛用于治疗抑郁症。本研究旨在评估EA联合AT治疗中风后失眠的疗效。总共120名与中风相关的失眠患者被随机分为三个干预组（每组n = 40）：EA治疗组、AT治疗组和EA联合AT治疗组。使用基于心肺耦合的睡眠质量评估系统、蒙特利尔认知评估量表（MoCA）和美国国立卫生研究院卒中量表（NIHSS）对睡眠效率和认知功能进行综合评估。结果显示，所有三种干预措施均显著提高了睡眠效率（EA组：78.23±4.19；AT组：75.5；EA联合AT组：80.97±4.21）和MoCA评分（EA组：24.2；AT组：24.2；EA联合AT组：27.2），联合治疗效果更佳。同样，所有治疗组的NIHSS评分均显著降低（EA组：6.2；AT组：7.2），尤其是在EA联合AT治疗组（EA联合AT组：4.3）。值得注意的是，治疗后分析显示，所有组的睡眠效率与MoCA评分之间均存在显著正相关，其中AT组的相关性最强（r = 0.87）。这些发现表明，EA联合AT治疗在治疗中风后失眠方面优于单一疗法。总之，本研究证实EA联合AT是改善中风相关失眠患者睡眠质量和认知功能的有效干预措施，为这一临床病症提供了一种有前景的治疗策略。
